Aim 2: Investigate whether tau pathology mediates or moderates the association of WMHs and amyloid markers with CDR‐SB, thus clarifying the complex interplay among these key neuropathological factors in AD progression. This evidence concerns the gene MAPT and Alzheimer disease.